HRP20120349T1 - Formulacija glatiramer acetata smanjenog volumenai postupci davanja - Google Patents

Formulacija glatiramer acetata smanjenog volumenai postupci davanja Download PDF

Info

Publication number
HRP20120349T1
HRP20120349T1 HRP20120349AT HRP20120349T HRP20120349T1 HR P20120349 T1 HRP20120349 T1 HR P20120349T1 HR P20120349A T HRP20120349A T HR P20120349AT HR P20120349 T HRP20120349 T HR P20120349T HR P20120349 T1 HRP20120349 T1 HR P20120349T1
Authority
HR
Croatia
Prior art keywords
unit dose
dose according
injection
subcutaneous injection
glatiramer acetate
Prior art date
Application number
HRP20120349AT
Other languages
English (en)
Croatian (hr)
Inventor
Ayelet@Altman
Doris@Saltkill
Dalton@L@@Tomlinson
Tomer@El@Gad
Original Assignee
Teva@Pharmaceutical@Industries@Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42283140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120349(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva@Pharmaceutical@Industries@Ltd filed Critical Teva@Pharmaceutical@Industries@Ltd
Publication of HRP20120349T1 publication Critical patent/HRP20120349T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20120349AT 2009-07-15 2012-04-18 Formulacija glatiramer acetata smanjenog volumenai postupci davanja HRP20120349T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27100909P 2009-07-15 2009-07-15
US27134009P 2009-07-20 2009-07-20
US33701110P 2010-01-29 2010-01-29

Publications (1)

Publication Number Publication Date
HRP20120349T1 true HRP20120349T1 (hr) 2012-07-31

Family

ID=42283140

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120349AT HRP20120349T1 (hr) 2009-07-15 2012-04-18 Formulacija glatiramer acetata smanjenog volumenai postupci davanja

Country Status (19)

Country Link
US (3) US20110060279A1 (https=)
EP (2) EP2275086B1 (https=)
JP (1) JP2012533540A (https=)
AR (1) AR077484A1 (https=)
AT (1) ATE549013T1 (https=)
AU (1) AU2010273234A1 (https=)
BR (1) BR112012000878A2 (https=)
CA (1) CA2697570C (https=)
DK (1) DK2275086T3 (https=)
EA (1) EA201270167A1 (https=)
ES (1) ES2383347T3 (https=)
HR (1) HRP20120349T1 (https=)
IL (1) IL217240A0 (https=)
MX (1) MX2012000687A (https=)
PL (1) PL2275086T3 (https=)
PT (1) PT2275086E (https=)
RS (1) RS52367B (https=)
WO (1) WO2011008274A2 (https=)
ZA (1) ZA201200586B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
CA2697570C (en) * 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CN104684603B (zh) * 2012-08-20 2017-11-24 卡贝欧洲有限公司 自动注射装置
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
PE20151577A1 (es) * 2013-03-08 2015-11-19 Teva Pharma Dispositivo inyector reutilizable para jeringa
US8591463B1 (en) 2013-03-08 2013-11-26 Teva Pharmaceutical Industries Ltd. Re-useable injector device for syringe
BR112015021548A2 (pt) * 2013-03-08 2017-07-18 Teva Pharmaceutical Industries Ltd dispositivo injetor reutilizável para seringa
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
EP3110375B1 (en) 2014-02-26 2022-01-26 Allergan, Inc. Intraocular implant delivery apparatus
US9415176B1 (en) 2015-01-22 2016-08-16 West Pharmaceutical Services, Inc. Autoinjector having an end-of-dose visual indicator
US9155775B1 (en) * 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
EP3534893A1 (en) * 2016-11-02 2019-09-11 To Pharmaceuticals LLC Combination therapy of cbd and copaxone
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2017924B3 (es) * 1985-10-11 1991-03-16 Duphar Int Res B V Inyector automatico.
NL8701091A (nl) * 1987-05-08 1988-12-01 Spruyt Hillen Bv Injectiepen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8926825D0 (en) * 1989-11-28 1990-01-17 Glaxo Group Ltd Device
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6454746B1 (en) * 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
SE518981C2 (sv) 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
AU2003275895B2 (en) * 2002-11-25 2009-02-05 Tecpharma Licensing Ag Auto-injector comprising a resettable releasing safety device
JP2007507541A (ja) * 2003-10-03 2007-03-29 ベイヒル セラピューティクス インコーポレーティッド 修飾型の規則正しいペプチドによる脱髄性自己免疫性疾患の治療方法
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
EP1796710A4 (en) * 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
AR052321A1 (es) * 2004-10-29 2007-03-14 Sandoz Ag Procesos para la preparacion de un polipeptido
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070161960A1 (en) * 2006-01-12 2007-07-12 Fu-Yuan Li Lancet device
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
MX2008016335A (es) * 2006-06-30 2009-01-21 Abbott Biotech Ltd Dispositivo automatico de inyeccion.
USD622374S1 (en) * 2006-09-06 2010-08-24 Abbott Biotechnology Ltd. Automatic injection device
CA2702437C (en) * 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
USD607558S1 (en) * 2008-09-19 2010-01-05 Becton Dickinson France S.A.S. Medicine injector
CA2697570C (en) 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration

Also Published As

Publication number Publication date
US20110066112A1 (en) 2011-03-17
BR112012000878A2 (pt) 2019-09-24
WO2011008274A2 (en) 2011-01-20
US9018170B2 (en) 2015-04-28
WO2011008274A4 (en) 2011-11-10
AU2010273234A1 (en) 2012-02-23
DK2275086T3 (da) 2012-07-09
EP2453907A2 (en) 2012-05-23
CA2697570C (en) 2011-11-01
US20110060279A1 (en) 2011-03-10
IL217240A0 (en) 2012-02-29
HK1152249A1 (en) 2012-02-24
US7855176B1 (en) 2010-12-21
ZA201200586B (en) 2013-10-30
EP2275086B1 (en) 2012-03-14
ATE549013T1 (de) 2012-03-15
WO2011008274A3 (en) 2011-09-22
ES2383347T3 (es) 2012-06-20
PL2275086T3 (pl) 2012-09-28
AR077484A1 (es) 2011-08-31
RS52367B (sr) 2012-12-31
JP2012533540A (ja) 2012-12-27
EP2275086A1 (en) 2011-01-19
MX2012000687A (es) 2012-09-07
PT2275086E (pt) 2012-05-18
EA201270167A1 (ru) 2012-08-30
CA2697570A1 (en) 2010-06-22

Similar Documents

Publication Publication Date Title
HRP20120349T1 (hr) Formulacija glatiramer acetata smanjenog volumenai postupci davanja
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
ES2716906T3 (es) Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab
JP2015187125A5 (https=)
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
JP2011241213A5 (https=)
HRP20120688T1 (hr) Re“im doziranja u liječenju traumatske ozljede mozga progesteronom
RU2015103107A (ru) Комбинированная композиция
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
FI3733712T3 (fi) Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä
Yang et al. Evaluation of collagen dermal filler with lidocaine for the correction of nasolabial folds: a randomized, double-blind, multicenter clinical trial
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
RU2011139015A (ru) Вызываемая медикаментозными средствами липоатрофия для косметических целей
WO2012044783A3 (en) Method of achieving a thymosin beta 4 concentration in a human patient
BR112012000773A2 (pt) Método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes humanos, método para o tratamento de pacientes humanos, método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes criticamente doentes, e método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes criticamente doentes com risco aumentado de eventos cardiovasculares
JP2013520447A5 (https=)
US20140171918A1 (en) Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
JP2014517038A5 (https=)
Aviv et al. Patterns of local site reactions to subcutaneous glatiramer acetate treatment of multiple sclerosis: a clinicopathological study
TW201129356A (en) Reduced volume formulation of glatiramer acetate and methods of administration
Nunns Tackling vulvodynia
Sun et al. Urolastic: A new medical liquid silicone rubber elastomer compound for penile augmentation in beagle dogs
Ahmad et al. A study on the effectiveness of intravenous tramadol in the management of severe traumatic pain in emergency department
AR122567A2 (es) Terapia de baja frecuencia con acetato de glatiramer
RU2574894C1 (ru) Способ лечения кожных заболеваний у животных